Cancer News and Research

Latest Cancer News and Research

Study suggests new experimental drug is better than standard morphine

A little-known morphinelike drug is potentially more potent, longer lasting and less likely to cause constipation than standard morphine, a study led by a Loyola University Health System anesthesiologist has found.

5 Jan 2011

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, and Pfizer Inc., today announced that the companies have expanded their collaboration directed to the development and commercialization of RNA-targeted medicines using Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform.

5 Jan 2011

Kiadis Pharma, Hospira sign license agreement to develop and commercialize ATIR hematology product

Kiadis Pharma, a biopharmaceutical company based in The Netherlands, announced that it has entered into a licensing agreement with Hospira, Inc., a global specialty pharmaceutical company, to develop and commercialize Kiadis Pharma's ATIR™.

5 Jan 2011

Vaccinex receives FDA clearance to initiate VX15/2503 Phase 1 clinical trial in advanced solid tumors

Vaccinex, Inc. announced today that it has received clearance from FDA and will initiate a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of therapeutic antibody candidate VX15/2503 in cancer patients with advanced solid tumors.

5 Jan 2011

DARA BioSciences closes registered public offering

On December 28, 2010, DARA BioSciences, Inc. announced that it planned to raise up to $4 million through a registered public offering of units comprised of shares of Series A convertible preferred stock and warrants to purchase shares of common stock. Due to strong demand for the offered securities, the Company increased the size of the offering to up to $4.8 million.

5 Jan 2011

Spectrum submits FUSILEV sNDA for treatment of colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced it submitted a supplemental New Drug Application with the U.S. Food and Drug Administration (FDA) for a Ready-to-Use formulation of FUSILEV (levoleucovorin) for Injection.

5 Jan 2011

Dutch scientists provide new insights into intestinal cancer through plant study

Dutch scientists have gained important new insights into intestinal cancer from studying a plant. The disease is called Peutz-Jeghers Syndrome, a hereditary disorder where people develop intestinal polyps that turn into malignant tumors.

5 Jan 2011

Tiny light source and sensors in endoscope may detect esophageal cancer more accurately

A tiny light source and sensors at the end of an endoscope may provide a more accurate way to identify pre-cancerous cells in the lining of the esophagus.

4 Jan 2011

Bioniche Life Sciences announces completion of Australian Offer and raises gross proceeds of A$12.5 million

Bioniche Life Sciences In., a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has successfully completed its Australian Offer of 8.6 million CHESS Depositary Instruments at A$1.45 per CDI, raising gross proceeds of A$12.5 million.

4 Jan 2011

FDA approves ImmunoCellular Therapeutics IND amendment for ICT-107 Phase II clinical trial

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) amendment to conduct a Phase II clinical trial in the U.S. of ICT-107, the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

4 Jan 2011

Single cancer cell could be detected in future using new test

Soon scientists will be able to detect a single cancer cell among the billions of cells that circulate in the human bloodstream. The method could detect whether the therapy has worked or even show which therapy would work best. The test depends on circulating tumor cells (CTCs) or cancer cells that have detached from the main tumor and are traveling to other parts of the body.

4 Jan 2011

Star Scientific develops moist snuff tobacco product with low carcinogenic levels

Star Scientific, Inc. reports that it has successfully developed a moist snuff tobacco product that has extremely low levels of carcinogens -- much lower than any snuff products currently in the marketplace. This new product has levels of tobacco-specific nitrosamines (TSNAs) -- recognized by scientists worldwide as one of the most powerful cancer-causing agents in tobacco leaf and smoke -- below 20 parts per billion (nanograms-per-gram moist weight, as used) in initial testing.

4 Jan 2011

Revolutions Medical reworks exclusive license with Traxyz for breast biopsy localization system

Revolutions Medical Corporation recently completed the reworking of a worldwide exclusive license with Traxyz, LLC for an image guided navigation system to convert over 50,000 conventional mammography systems for use as a high accuracy breast biopsies system (BBS). This BBS facilitates accurate and fast non-palpable lesions and micro calcification localization in the treatment of breast cancer.

4 Jan 2011

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.

4 Jan 2011

Genesis Biopharma closes private offerings to purchase 845,000 shares of common stock

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced that it closed private offerings in December and October 2010 pursuant to which it entered into definitive agreements with accredited investors to purchase a total of 845,000 shares of the Genesis Biopharma common stock for a purchase price of $1.00 per share.

4 Jan 2011

Fresenius Medical Care to acquire Euromedic's dialysis service business

Fresenius Medical Care AG & Co. KGaA, the world's largest provider of dialysis products and services, today announced the signing of a purchase agreement to acquire International Dialysis Centers ("IDC"), Euromedic International's ("Euromedic") dialysis service business.

4 Jan 2011

14th World Conference on Lung Cancer: Online registration opens

Online registration opens today for the 14th World Conference on Lung Cancer, which will be held in Amsterdam, The Netherlands, from July 3-7, 2011.

4 Jan 2011

Caution over frequent use of diagnostic tests for kids

The rapid growth in use of medical diagnostic imaging, such as CT scans, has led to widespread concern about radiation exposure in adults and the potential for future cancer risk in patients undergoing these tests.

4 Jan 2011

Take control of your healthcare

Medical decisions are too important to leave in the hands of doctors. That is why Dr. Steven Z. Kussin recently launched a campaign, www.MedicalAdvocate.com, to teach Americans how to take control of their healthcare by becoming their own patient advocate.

4 Jan 2011

Fundamental similarities in response to wasp infection and blood cancer development

Tiny parasitoid wasps can play an important role in controlling the populations of other insect species by laying their eggs inside the larvae of these species. A newly hatched wasp gradually eats the host alive and takes over its body.

4 Jan 2011

Cancer News and Research

Latest Cancer News and Research

Study suggests new experimental drug is better than standard morphine

Santaris Pharma, Pfizer expand RNA-targeted medicine collaboration

Kiadis Pharma, Hospira sign license agreement to develop and commercialize ATIR hematology product

Vaccinex receives FDA clearance to initiate VX15/2503 Phase 1 clinical trial in advanced solid tumors

DARA BioSciences closes registered public offering

Spectrum submits FUSILEV sNDA for treatment of colorectal cancer

Dutch scientists provide new insights into intestinal cancer through plant study

Tiny light source and sensors in endoscope may detect esophageal cancer more accurately

Bioniche Life Sciences announces completion of Australian Offer and raises gross proceeds of A$12.5 million

FDA approves ImmunoCellular Therapeutics IND amendment for ICT-107 Phase II clinical trial

Single cancer cell could be detected in future using new test

Star Scientific develops moist snuff tobacco product with low carcinogenic levels

Revolutions Medical reworks exclusive license with Traxyz for breast biopsy localization system

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

Genesis Biopharma closes private offerings to purchase 845,000 shares of common stock

Fresenius Medical Care to acquire Euromedic's dialysis service business

14th World Conference on Lung Cancer: Online registration opens

Caution over frequent use of diagnostic tests for kids

Take control of your healthcare

Fundamental similarities in response to wasp infection and blood cancer development

Understanding the DNA Damage Response in Innate Immunity eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in